Lurbinectedin for cancers with specific EWS-related gene fusions
Treatments studied
Part of Cancer clinical trials.
This early-phase study tests lurbinectedin, a chemotherapy medicine, in children and young adults whose solid tumors have a specific “FET fusion” gene change. It may help shrink tumors that have come back or did not respond to prior treatment, depending on the exact fusion type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 10 years old.
- Your tumor must have a confirmed FET gene fusion (involving EWSR1, FUS, or TAF15) using lab tests like sequencing, PCR, or FISH.
- Your cancer must be recurrent or relapsed and have failed prior treatment (for Phase 2, it’s Ewing sarcoma with the EWS-FLI1 fusion).
- Your performance status must be good enough for study treatment (ECOG 0–1 if over 16, or Lansky 70+ if under 16).
- Your most recent scans must show measurable disease within 28 days of starting treatment, and you must meet blood, liver, kidney, and heart requirements.
- You cannot have had lurbinectedin or trabectedin before, and you must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests lurbinectedin, a cancer medicine, by itself (no other drugs) in children and young adults whose Ewing sarcoma has come back or did not respond to prior treatment. It aims to see how safe the drug is and whether it can help control the cancer.
This trial is testing a new drug called xaluritamig for children, teens, and adults with Ewing sarcoma that has come back or is not responding to treatment. The goal is to see if this drug can shrink the cancer or stop it from growing.
This trial tests a combination of two chemotherapy drugs (lurbinectedin and irinotecan) for people with desmoplastic small round cell tumor (DSRCT) that has spread or cannot be removed by surgery. It is for patients whose cancer has gotten worse after at least one prior treatment.
This trial tests new drugs for young people with Ewing sarcoma or similar sarcomas that have come back or not responded to standard treatment. The goal is to see if these drugs can shrink or control the cancer.
This trial tests a new immunotherapy that targets a specific protein change found in Ewing sarcoma and desmoplastic small round cell tumors (DSRCT). The therapy is designed to help your immune system recognize and attack cancer cells. It may be an option if you have already received standard chemotherapy and your tumor has a certain genetic marker.
This trial tests a new combination of two drugs, lurbinectedin and durvalumab, for people with extensive-stage small cell lung cancer (ES-SCLC) who have already received four cycles of standard platinum-based chemotherapy along with durvalumab. The goal is to see if this combination can help control the cancer further.
Hear when a new Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.